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O B J E C T I V E S We sought to determine: 1) whether F-18-ﬂuorodeoxyglucose (FDG) positron
emission tomography (PET) parameters identify high-risk patients who gain beneﬁt from revasculariza-
tion; 2) whether there is a cut point for such beneﬁt; and 3) predictors of outcome in patients with severe
left ventricular (LV) dysfunction due to coronary artery disease.
B A C KG ROUND Patients with ischemic LV dysfunction might beneﬁt from revascularization but
not without risk. The FDG PET imaging can detect viable myocardium that recovers after revasculariza-
tion. In the PARR-2 (PET and Recovery Following Revascularization-2) trial, FDG PET imaging showed a
nonsigniﬁcant trend for improved outcome compared with standard care. Understanding the predictors
of outcome from this prospective trial should help better identify patients at risk and which patients
most beneﬁt from revascularization.
METHOD S This post hoc analysis included 182 patients with left ventricular ejection fraction (LVEF)
35% and coronary artery disease, being considered for revascularization work-up, and randomized to the
PET arm of PARR-2. The primary outcome was a composite of cardiac death, myocardial infarction, or cardiac
repeat hospital stay at 1 year.
R E S U L T S There is an interaction between PET mismatch and protocol revascularization such that higher
mismatch, when combined with revascularization, yields fewer primary outcome events (p  0.02). On the
basis of adjusted Cox modeling, with reduced mismatch (7%), the risk is not signiﬁcantly different with or
without revascularization. As mismatch increases above this mark, risk is reduced with revascularization.
Increasing creatinine (for a 10-mol/l increase: hazard ratio: 1.03, 95% conﬁdence interval: 1.01 to 1.06,
p  0.010) is also associated with increased risk, whereas decreasing LVEF (for a 2% decrease: hazard ratio:
1.08, 95% conﬁdence interval: 0.99 to 1.18, p  0.087) trends toward an association with increased risk.
CONC L U S I O N S In this post hoc analysis, patients with ischemic cardiomyopathy with larger
amounts of mismatch have improved outcome with revascularization. Renal function was also an
independent predictor of outcome. The FDG PET seems to deﬁne high-risk patients that gain beneﬁt
from revascularization. (PET and Recovery Following Revascularization [PARR 2]; NCT00385242) (J Am
Coll Cardiol Img 2009;2:1060–8) © 2009 by the American College of Cardiology Foundation
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1061atients with ischemic cardiomyopathy might
benefit from revascularization but have signifi-
cant perioperative risk (1–3). Previous studies have
shown that surgical mortality can vary from 5% to
7% (1,4–6). Therefore it is crucial to identify those
atients who would benefit from revascularization.
-18-fluorodeoxyglucose (FDG) positron emission
omography (PET) imaging has long been regarded as
he most sensitive method for the detection of viable
ecoverable myocardium (7). Outcome data from ret-
ospective and/or observational studies have indicated
hat FDG PET can define viable myocardium in
atients with left ventricular (LV) dysfunction, and if
hese patients do not undergo early revascularization
hey are at high risk for death and further cardiac
vents (4,8–17). This is supported by 2 meta-analyses
hat showed that patients with viable myocardium
ho received revascularization had better survival
ompared with those receiving medical therapy (7,18).
See page 1069
he aforementioned studies were observational in
ature and could not determine whether clinical
ecisions guided by FDG PET imaging data al-
ered patient outcome. Until recently data from
andomized controlled trials were lacking.
The PARR-2 (PET and Recovery Following Re-
ascularization) trial was the first randomized con-
rolled trial to determine whether management as-
isted by FDG PET achieves a better clinical outcome
han standard care without FDG PET available, in
atients with severe LV dysfunction (19).
The results at 1 year showed that there was a
rend toward benefit in the PET group compared
ith the standard care group, but this was not
tatistically significant. However, there was a 25%
onadherence rate to PET management recom-
endations. When adherence to PET recommen-
ations for revascularization or revascularization
ork-up was considered, significant benefits were
bserved in the FDG PET arm.
The utility of FDG PET might be best realized
n this subpopulation that adhered to PET imaging
ontreal Heart Institute, Université de Montréal, Montréal, Québec, Ca
ospitalier Universitaire de Sherbrooke, Sherbrooke, Québec, Canada. The
nstitute for Health Research (grant # MCT 37412), the Heart and Stroke
s NA4316 and T5222), and HFSO Program Grant on Molecular Functi
upplemented by a University/Government/Industry Program: the Ontario R
ordion (ORDCF-00-May-0710), to provide part-time coordinator salary su
y the HSFO. None of the authors have any holdings that would present aanuscript received October 2, 2008; revised manuscript received January 21ecommendations. In this post hoc analysis we
ought to identify: 1) whether FDG PET parame-
ers could identify high-risk patients who would
ain significant benefit from revascularization; 2) at
hat cut point this benefit might be realized; and
) to better define imaging predictors of outcome in
atients with severe ischemia and LV dysfunction.
E T H O D S
he methods of the PARR-2 trial have been
ublished separately (19,20). Details of methodol-
gy relevant to the patients included the current
tudy are described in the following text.
atients. Included in this substudy were patients
andomized to the FDG PET arm of the PARR-2
rial. Candidates for the PARR-2 trial were:
) patients being considered for revascularization or
evascularization work-up; 2) patients being consid-
red for transplantation work-up; 3) patients being
onsidered for heart failure work-up; or 4)
ny patient for whom FDG PET viability
maging might be considered useful by the
ttending physician for decision-making
nd who met other inclusion criteria. El-
gible patients were included if they were
ver 18 years of age; had an LVEF 35%
ocumented by radionuclide angiogram
RNA), LV angiogram, or echocardiogra-
hy; and had a high suspicion of coronary
rtery disease on the basis of coronary
ngiography, previous revascularization,
revious myocardial infarction (MI) (4
eeks) verified by chart review, and/or
ositive stress perfusion imaging for scar with or
ithout ischemia. Excluded were patients: in whom
therapy decision had already been determined
uch that the attending physician would not alter
anagement on the basis of any potential viability
ndings; and those who had already had FDG
iability imaging. Also excluded were those: with
omorbidities that would affect survival; 4 weeks
ost-MI; already identified to be unsuitable for revas-
ularization; requiring emergency revascularization;
; and the #Division of Nuclear Medicine, Centre
dy was supported by grants from the Canadian
ndation of Ontario Grant-in-Aid (HSFO Grant
nd Imaging (grant #PRG6242). The funding was
rch and Development Challenge Fund with MDS
t. Dr. Beanlands is a Career Investigator supported
flict of interest to the publication of these data.
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1062ith valvular disease that required surgery; or who
ere geographically inaccessible.
Data from the patients randomized to the PET
rm of the PARR-2 trial were included in the
resent analysis if the patient had complete baseline
ata available, including: baseline RNA, baseline
lood work, and having undergone FDG PET.
atients were excluded if they were found in
ork-up to not have coronary stenoses 50% or if
hey had poor-quality uninterpretable FDG PET
maging. Patients who had events before PET
maging were also excluded from this analysis;
ecause such patients would not have had complete
aseline data before the event.
maging. Patients underwent RNA imaging at
aseline. The RNAs were acquired with a standard
lectrocardiogram-gated equilibrium Technetium-
9m-red blood cell blood pool imaging protocol
19,21). The PET perfusion imaging was acquired
t rest with a standard protocol with rubidium-82
r N-13-ammonia (19–22). Full details of PET
maging protocols are provided elsewhere (19–23).
he images were analyzed to assess myocardial
erfusion-metabolism mismatch and match (scar)
Figure 1. Examples of Images and Reconstructed Polar Maps in
(A) Perfusion (left) and F-18-ﬂuorodeoxyglucose (FDG) (right) imagi
axis (HLA) planes. Reduced perfusion with predominately maintaine
walls of the left ventricle (LV). (B) Polar maps (scale is %): top row
maps; middle row is the normalized perfusion defect and FDG defe
the total LV myocardium, 8% was scar, and 20% was mismatch. The
that the patient would be expected to improve after revascularizati
week, awaiting surgery.xpressed as a percentage of the LV, with our wreviously described scoring method (19–21) as
llustrated in Figure 1.
DG PET-ASSISTED MANAGEMENT ARM. As per the
ARR-2 trial, these PET parameters were included
ith clinical parameters in a previously derived
odel that yielded a point estimate and 95%
onfidence interval for predicted LV function re-
overy after revascularization (20,21). Patients were
lassified as having low, moderate, or high likeli-
ood of recovery if adequate revascularization could
e achieved. Interpreting physicians considered the
xtent of scar and mismatch in their interpretation.
standard clinical report detailing the extent of
car (20), total viable myocardium, and mismatch
all as a percent of the left ventricle); the likelihood
or recovery was faxed and delivered to the treating
hysician (20).
ROTOCOL REVASCULARIZATION VERSUS MEDICAL
HERAPY. Once initial testing and evaluation were
ompleted, the treating physician would then con-
ider the PET imaging data in the context of the
ndividual patient and make a decision to proceed or
ot with revascularization (or revascularization
Enrolled Patient
n the short-axis (SA), vertical-long-axis (VLA), and horizontal-long-
G uptake (mismatch) is noted in the anterior, septal, and lateral
ing the raw perfusion (left) and raw FDG uptake (right) polar
owest row is the scar score (left) and mismatch score (right). Of
erpretation was that there was a large amount of mismatch and
The patient was referred for revascularization but died within 1an
ng i
d FD
show
ct; l
int
on.ork-up in those without recent angiography).
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1063uch revascularizations were considered protocol
evascularization. These management plans were
eviewed and confirmed at 8 weeks after enroll-
ent. Hospital stays associated with protocol revas-
ularization were not counted as events. Those
atients without protocol revascularization were
onsidered as having medical therapy.
Patients were censored at the time of events (see
he Statistical Analysis text). As such, patients with
vents before a scheduled revascularization (having
een censored at the time of the event) were consid-
red to be in the nonrevascularized (medical) group.
iven that decisions for aneurysm surgery might be
ifferent than revascularization alone, patients who
nderwent aneurysm resection were excluded.
ardiac event variable deﬁnitions and measure-
ent. The primary event of interest was the occur-
ence of any of the following within 1 year of
andomization: cardiac death, MI, cardiac trans-
lantation, or hospital stay due to cardiac cause such
s unstable angina or heart failure. Elective admis-
ions for procedures such as primary prevention
mplantable cardioverter-defibrillator (ICD) were
ot counted as events. Noncardiac deaths were not
ounted as events. Events were reviewed and veri-
ed by an adjudication committee blinded to the
esults of the FDG PET scan (19). The definitions
f each variable and the timing of their measure-
ent have been described previously in the
ARR-2 trial design (19,20).
Table 1. Patient Characteristics
Variable
PET Arm
(n  182)
95% Conﬁdence
Interval
Age, mean (SD) 63 (10) (61–64)
Male, n (%) 155 (85) (80–90)
Baseline ejection fraction,
mean (SD)
26 (6) (25–27)
Diabetes, n (%) 72 (40) (32–47)
Prior infarction, n (%) 150 (82) (76–88)
Angiography in previous
6 months, n (%)
94 (52) (44–59)
Prior coronary artery bypass
grafting, n (%)
39 (21) (16–28)
Angina (CCS class II–IV), n (%) 81 (45) (37–52)
Dyspnea (NYHA functional class
II–IV), n (%)
151 (83) (77–88)
Creatinine (mol/l), mean (SD) 112 (66) (102–122)
FDG PET imaging scar score %,
mean (SD)
18 (9) (16–19)
FDG PET imaging mismatch
score %, mean (SD)
5 (6) (4–6)
Protocol revascularization, n (%) 83 (46) (38–53)
CCS  Canadian Cardiovascular Society; FDG  F-18-ﬂuorodeoxyglucose;eNYHA  New York Heart Association; PET  positron emission tomography.tatistical analysis. Continuous measures are pre-
ented as mean  SD. Categorical measures are
resented as frequencies with percentages. Because
he primary objective of this substudy was to deter-
ine whether FDG PET parameters could identify
igh-risk patients who would gain significant ben-
fit from revascularization, multivariable Cox pro-
ortional hazard models were used to assess the
ndependent prognostic value of the protocol revas-
ularization and PET parameters (mismatch and
car), including all 2-way interactions. Other base-
ine characteristics included in Table 1 with p values
0.20 on the basis of univariable Cox proportional
azard models were added to control for confound-
ng with stepwise selection methods resulting in the
nal model given in Table 2.
To illustrate the observed interaction of revascu-
arization and mismatch, hazard ratios were deter-
ined for mismatch levels with the interaction
stimates from the adjusted Cox model with mis-
atch as a continuous variable (Fig. 2). Previous
tudies have defined mismatch as dichotomous
ariable. We therefore also performed secondary
nalyses evaluating mismatch as a dichotomous
ariable in the adjusted Cox model with an inter-
ction test. A p value 0.05 was considered statis-
ically significant. Statistical calculations were car-
ied out with SAS software (SAS Institute Inc.,
ary, North Carolina).
E S U L T S
linical characteristics. Among the 218 patients who
ere enrolled in the PET arm, 182 met the sub-
tudy inclusion criteria and had complete and in-
erpretable data (Table 1). Excluded were: 11 pa-
ients allocated to the PET group but who did not
ndergo PET imaging; 9 patients who initially
eemed to meet inclusion criteria but were found to
ave an EF 35% on the RNA done at the time of
Table 2. Multivariable Cox Proportional Hazard Model
Variable
Parameter
Estimate
Standard
Error
p
Value
Protocol revascularization 0.428 0.396 0.280
Mismatch size 0.050 0.036 0.161
Revascularization/mismatch
interaction
0.171 0.074 0.020
Creatinine (10 mol/l increase) 0.032 0.013 0.011
Ejection fraction (2% increase) 0.075 0.044 0.087nrollment (2 patients had EF 35% and did not
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1064ndergo PET imaging); 6 patients were subse-
uently found to not have any significant coronary
tenoses; 4 patients had poor-quality PET imaging
ata whereby no scar or mismatch score could be
ccurately determined (1 of these patients was also
patient without significant coronary artery disease
n angiography); 2 patients had events preceding
ET imaging (1 such patient had an EF 35%); 5
atients had no baseline RNA for EF or no creat-
nine measurement; and 3 patients underwent an-
urysm resection. In all, 36 patients had 40 exclu-
ion criteria, leaving 182 patients with complete and
nterpretable data for analysis.
The baseline characteristics of these patients are
rovided in Table 1. Patients were, on average, 63 
0 years of age with a mean EF of 26  6% and a
Hazard Ratios and 95% Conﬁdence Interval at Various Levels
d as a Continuous Variable
on from the multivariable model. For those with mismatch of
cant difference in the risk of the primary outcome if revascular-
red with not done. As mismatch increases (i.e., 7%), there is a
rimary outcome for those who undergo revascularization. For
f 7%, there is a 0.46 times lower risk for the primary outcome if
e.
Table 3. Medications Used by Patients in the
Revascularization and Medical Therapy Groups
Medication
Medical
Therapy
Protocol
Revascularization
Antiplatelet and/or
anticoagulation
91 (92%) 72 (87%)
Nitrates 39 (39%) 36 (43%)
Beta-blockers 77 (78%) 62 (75%)
ACE inhibitors or ARB 90 (91%) 71 (86%)
Digoxin 37 (37%) 24 (29%)
Diuretics 78 (79%) 59 (71%)wACE  angiotensin-converting enzyme; ARB  angiotensin-receptor blocker.ean creatinine of 112  66 mol/l. The mean
ismatch score in the total population was 5 6%,
nd mean scar score was 18  9%. Of the 182
atients, 83 (46%) patients underwent protocol
evascularization, of whom 55 (66% of protocol
evascularizations) underwent coronary artery by-
ass grafting. The mean mismatch and scar scores
ere 6  7% and 15  8%, respectively, in the
atients who underwent revascularization compared
ith 4  4% and 20  9%, respectively, in those
reated with medical therapy. Among those who
nderwent protocol revascularization, 3 (4%) had
CD device therapy compared with 8 (8%) in the
edical group during the 1-year follow-up period.
uring the course of the trial the American College
f Cardiology/American Heart Association guide-
ines for ICD therapy were published that recom-
ended ICD for primary prevention in severe LV
ysfunction as a Level I indication (24). As such, a
ecommendation was sent to the treating physicians
f enrolled patients to consider device therapy, if
he patient met appropriate criteria. Table 3 shows
he medical therapy in each group.
ardiovascular events. Fifty-four patients had a pri-
ary outcome. Of these 54 patients, cardiac death
as first event in 11, MI in 5, transplantation in 2,
nd repeat hospital stay because of a cardiac cause in
6 patients (Tables 4 and 5). Eighteen patients had
cardiac death within 1 year of enrollment, 11 as a
rst event and 7 as a subsequent event. There were
noncardiac deaths (not counted as cardiac events),
of which occurred later than the patient’s first
ardiac event.
ultivariable analysis. When the interaction of mis-
atch and protocol revascularization was considered
n the multivariable Cox proportional hazard model,
here was a statistically significant effect on the pri-
ary outcome (p  0.020) (Table 2). Increasing
reatinine (for a 10-mol/l increase: hazard ratio 
.03, 95% confidence interval: 1.01 to 1.06, p 
.010) is also associated with increased risk, and
ecreasing EF (for a 2% decrease: hazard ratio: 1.08,
5% confidence interval: 0.99 to 1.18, p  0.087)
rends toward an association with increased risk. The
djusted model in Table 2 summarizes that the inter-
ction of mismatch and protocol revascularization is
till statistically significant, even after adjusting for
reatinine and EF.
To illustrate the observed interaction of revascu-
arization and mismatch, in Table 2, hazard ratios
ere determined for mismatch levels with the
nteraction estimates from the adjusted Cox modelFigure 2. Interaction
of Mismatch Measure
The ﬁgure is a derivati
7% there is no signiﬁ
ization is done compa
decreased risk of the p
those with mismatch oith mismatch as a continuous variable (Fig. 2). In
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1065atients with lower levels of mismatch (7%), the
isk of the primary outcome is not significantly
ifferent with or without revascularization. At
igher levels of mismatch, 7%, the risk of the
omposite event decreases if the patient undergoes
evascularization. When mismatch  7, there is a
.46 (95% confidence interval: 0.22 to 0.97) times
ower risk of the primary outcome if the patient
ndergoes revascularization compared with not be-
ng revascularized (Fig. 2).
In response to this finding we analyzed the cut
oint of 7% as a dichotomous variable (Fig. 3).
hose with mismatch 7% had a significantly
educed incidence of the primary outcome with
evascularization compared with medical manage-
ent (3 [13%] vs. 9 [56%], p 0.015). No patients
0%) with mismatch 7% who received revascular-
zation died, compared with 2 (13%) who were
edically managed. The small number of deaths
oes not allow analysis of this end point. Those
atients with a mismatch of7% had no significant
ifference in the primary outcome when revascular-
zation was undertaken, compared with not under-
aken (18 [31%] vs. 24 [29%], p  0.923). Nine
11%) patients suffered cardiac death in the medi-
ally managed group with mismatch 7% com-
ared with 7 (12%) patients in the revascularized
roup.
Given that previous published reports have sug-
ested a cut point of 5% for predicting adverse
Table 4. Distribution of First Events Between Medical Therapy a
No Event Cardiac Death M
Medical therapy 66 6 (5)
Protocol revascularization 62 5 (2)
Total 128 11 (7)
  number of cardiac deaths that were not the ﬁrst event for the patient; M
Table 5. Cardiac Repeat Hospital Stay Due to Cardiac Arrest,
Angina, and CHF in Medical Therapy and Protocol
Revascularization Groups
Medical Therapy
(n  22)
Protocol
Revascularization
(n  14)
Cardiac arrest 1 (5%) 1 (7%)
CHF 14 (64%) 8 (57%)
Angina 3 (14%) 4 (29%)
CHF and angina 2 (9%) 0
CHF with others 2 (9%) 1 (7%)
Others were severe mitral regurgitation, ventricular tachycardia, or atrial
ﬁbrillation.oCHF  congestive heart failure.utcome without revascularization (4), we analyzed
% and 6% in addition to the 7% cut point
dentified in the preceding text. Statistically signif-
cant effects of revascularization were observed with
ismatch 6% (p  0.036) or 7% (p  0.015)
ut not with mismatch 5% (p  0.216), although
he overall interaction of mismatch and protocol
evascularization was only significant for the cut
oint of 7% (p  0.020) and not 5% (p  0.771) or
% (p  0.054, a trend).
I S C U S S I O N
n this post-hoc observational analysis of the
ARR-2 trial we found that, as the amount of
yocardial perfusion-metabolism mismatch (as a
easure of hibernation) increases, there is a pro-
ressive increase in a patient’s benefit from revas-
ularization. To our knowledge this is the first study
o consider the relationship among mismatch as a
ontinuous variable, revascularization, and out-
omes and to use this relationship to determine a
ismatch cut point for revascularization outcome
enefit. In this prospective study, patients with
schemic cardiomyopathy with larger amounts of
ismatch—specifically those with mismatch
7%—had an improved outcome with revascular-
zation. Also of relevance is that there was no
ignificant interaction between PET-defined scar
nd revascularization, suggesting that mismatch is
he relevant parameter for determination of these
utcome benefits of revascularization. Other pa-
ameters in the adjusted model, namely creatinine
nd EF, were predictors or trended toward being
redictors of outcome regardless of whether the
atient had revascularization or not. Even after
djusting for creatinine and EF, increasing amounts
f mismatch defined by PET predicted increasing
enefit from revascularization.
DG PET imaging predictors of outcome. In a recent
eta-analysis, of observational and predominately
etrospective data, Schinkel et al. (7) have shown
hat using PET and other viability imaging meth-
Protocol Revascularization Groups
Transplant Repeat Hospital Stay Total First Events
2 22 33
0 14 21
2 36 54
yocardial infarction.nd
I
3
2
5
I  mds can identify high-risk patients at greater risk of
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1066ardiac events if they do not undergo revasculariza-
ion. This meta-analysis report also pointed out the
ffect of Revascularization or Medical Therapy
of revascularization or medical therapy on primary outcome (A)
death (B) in patients with mismatch dichotomized to either
7%. In A for patients with mismatch of 7%, there is no signiﬁ-
nce in the primary outcome if revascularization is done com-
not done (p  0.923). In patients with mismatch 7%, there is a
y lower percentage of patients who experience the primary out-
ascularization is undergone compared with not undergone (p 
for patients with mismatch of 7%, the percent of cardiac
n revascularization is done compared with not done is not very
o patients with mismatch 7% who received protocol revascular-
compared with 2 (15%) who were medically managed.eed for prospective data in this field, as was (cquired in this study. The authors also report that
here is a wide heterogeneity in dichotomous via-
ility criteria for mismatch and viability that are
sed from study to study—often arbitrarily defined
ithout definitive support for a given cut point.
Previous data evaluating the relationship of via-
ility extent and the outcome response to revascu-
arization are limited. Our prospective study is
nique in that we evaluated mismatch as a contin-
ous variable in a multivariable Cox model that
ielded a cut point of 7%. There was an increase in
he benefit of revascularization as mismatch in-
reased. In analysis of a mismatch of 7% as a
ichotomous variable, those patients with a mis-
atch of 7% gain significant outcome benefit
hen revascularization is undertaken compared
ith medical therapy (p  0.015) (Fig. 2). This cut
oint requires prospective evaluation in another
atient population.
Our findings are consistent with previous co-
orts: in patients with mismatch, revascularization
educes undesirable clinical events compared with
edical management alone. One previous study
eported a cut point of 1 of 13 (7.6%) segments of
he left ventricle, but this was arbitrarily selected,
nd there was no analysis of the relationship be-
ween the presence of mismatch and impact of
evascularization on clinical outcomes (9). Di Carli
t al. (4) showed that patients with a mismatch of at
east 5% had a higher event rate when treated
edically. In another study, with FDG SPECT,
esideri et al. (14) showed that the risk of death is
ignificantly increased when the extent of mismatch
xceeds 20%. These studies were retrospective. As
uch, it was unclear what role FDG PET imaging had
n decision-making. The current study used a prospec-
ive design where FDG PET was applied in decision-
aking as part of the primary design of the PARR-2
rial.
In the current study, another predictor of out-
ome in the adjusted model was creatinine, and EF
howed a trend toward increased risk. Previous
tudies have been variable as to whether EF was a
redictor of outcome. Lee et al. (9) reported that
atients with low EF 30% had higher cardiac
ortality compared with those with an EF 30%.
ikewise, Yoshida and Gould (12) reported a lower
ortality rate for patients with an EF 43%.
revious studies where EF was not a predictor of
utcome attributed this finding to the fact that the
ajority of patients included had severely depressed
VEF with mean EFs between 25% and 34%A
B
Figure 3. E
The effect
and cardiac
7% or 
cant differe
pared with
signiﬁcantl
come if rev
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1067n independent predictor of outcome in our study,
espite our patient population having severely re-
uced LVEF (26  6%). That our study demon-
trated a trend, whereas others did not, might be
ue to the fact that we considered a composite end
oint including death, MI, and cardiac repeat hos-
ital stay and a larger sample size than previous
tudies (4,8,9,12,14).
No previous viability imaging studies have re-
orted creatinine as a predictor of outcome. This
ight prove to be a useful clinical parameter to help
istinguish a subgroup of patients who are at higher
isk. This is increasingly relevant, due to the rising
ncidence of chronic kidney disease (CKD) in
atients with heart failure. In addition viability
ssessment with other techniques, including cardiac
agnetic resonance and computed tomography, carry
isks for the patient with CKD (25,26). As such, in
atients with CKD, FDG PET is the preferred
dvanced imaging approach for viability assessment.
tudy limitations. First, this is a substudy, and hence
t has all of the inherent limitations of a post hoc
nalysis and warrants confirmation in a larger study.
owever, this study’s prospective design as part of a
andomized controlled trial has advantages over
revious retrospective studies. The sample size,
lthough small, was powered to detect the interac-
ion and also an absolute difference of 35% or
reater on the basis of post hoc influence analysis
ith the Fisher exact test. Therefore, a delta of 39%
ould be statistically significant. Nevertheless, be-
ause of the overall small number of events, small
hanges in events could affect the difference be-
ween the groups or the cut point, further empha-
izing the need for verification in a larger study.
Second, our overall number of fatal events wasValue of metabolic imaging with positron Elhendy A, Ferraortality with statistical techniques. Lower mortal-
ty likely reflects patient selection and/or improve-
ents in medical therapy for heart failure. Third,
he multivariable Cox proportional hazard models
re limited by the number of events. Accordingly, to
revent overfitting of the multivariable Cox propor-
ional hazard models, only baseline variables that
ere significant at a 0.20 significance level or lower
ere considered (i.e., creatinine and EF).
O N C L U S I O N S
n this prospective observational analysis with a
omposite outcome, there is a progressive increase
n patient benefit from revascularization as the
mount of mismatch (a measure of hibernating
yocardium) increases. Patients with ischemic car-
iomyopathy with larger amounts of mismatch,
pecifically those with mismatch 7%, might have
mproved outcome with revascularization. Another
ndependent predictor of outcome was impaired
enal function, whereas lower EF demonstrated a
rend toward an association with increased risk.
hese parameters seem useful in defining high-risk
atients. The FDG PET imaging is useful in
efining a subset of patients with myocardial
erfusion-metabolism mismatch that could gain
ignificant outcome benefit from revascularization.
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